Skip to main content
Fig. 17 | Malaria Journal

Fig. 17

From: The past, present and future of anti-malarial medicines

Fig. 17

Key compounds in the discovery of DM1157. Initial combination of the reversal agent, imipramine, with the CQ core resulted in the potent RCQ compound D2. Subsequent replacement of the reversal agent with 1-(2,2-diphenylethyl)piperazine (D3), and further modification with pyridine rings led to improved potency and cLogP values for the optimized compound

Back to article page